Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Lakefront Biotherapeutics NV files with the SEC in its annual reports.
In EUR millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
130
127
279
835
478
234
241
240
276
1,112
Cost of revenue
1.63
12.1
34.9
29.7
Gross profit
233
229
241
1,083
Research and development
140
219
316
420
524
321
270
241
335
459
Operating income
-11.5
-89.8
-47.1
369
-179
-172
-131
-88.3
-188
295
Pre-tax income
54.2
-116
-31.4
149
-310
-119
-70.8
5.63
-3.09
301
Income tax
0.24
0.2
0.82
-0.17
1.23
1.39
0.57
9.61
-1.8
-18.6
Income from continuing operations
-32.2
149
-311
-121
-71.4
-3.99
-1.28
319
Net income
54
-116
-29.3
150
-305
-103
-218
212
74.1
321
EPS, basic
1.18
-2.34
-0.56
2.60
-4.69
-1.58
-3.32
3.21
1.12
4.87
EPS, diluted
1.14
-2.34
-0.56
2.49
-4.69
-1.58
-3.32
3.21
1.12
4.87
Balance sheet
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
973
1,151
1,291
1,862
2,135
2,233
508
167
64.2
87.9
Short-term investments
0
3,919
3,026
2,470
3,586
3,518
3,053
2,910
Receivables
9.73
28
18.6
54
148
111
40.4
28.4
47.5
20.7
Inventory
0.3
0.28
0.28
0.26
0.04
20.6
52.9
74
51.2
22.5
Total current assets
1,007
1,198
1,329
5,866
5,369
4,862
4,237
3,862
3,339
3,079
Property, plant and equipment
15
16.7
23.1
40.7
68.3
106
127
111
105
71.9
Lease right-of-use assets
0
25.3
35.1
15.1
17.5
8.72
Goodwill
69.8
69.6
70
Intangible assets
1.02
2.5
3.63
24.9
67.6
60.1
146
128
165
0.85
Total assets
1,083
1,286
1,439
6,069
5,718
5,193
4,734
4,357
4,136
3,407
Accounts payable
31.9
48.3
68.9
143
176
138
149
135
98.9
105
Total current liabilities
104
172
220
572
635
566
523
428
335
153
Lease liabilities
0
19.6
23
19.7
14.7
4.94
8.24
5.19
Total liabilities
325
274
225
3,193
3,047
2,550
2,208
1,562
1,239
171
Paid-in capital
649
993
1,278
2,704
2,728
2,730
2,736
2,737
2,737
2,737
Retained earnings
-112
-211
-298
-109
-335
-367
-497
-228
-134
211
Total equity
759
1,012
1,214
2,876
2,670
2,643
2,526
2,796
2,897
3,236
Total liabilities and equity
1,083
1,286
1,439
6,069
5,718
5,193
4,734
4,357
4,136
3,407
Cash flow statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
54
-116
-29.3
150
-305
-103
-218
212
74.1
321
Cash from operations
239
-147
-142
3,209
-427
-504
-501
-406
-320
-257
Capital expenditures
-4.46
-5.31
-10.4
-22.4
-42.5
-54.2
-27.4
-18.7
-16.7
-13.7
Cash from investing
-7.29
-0.55
-15.9
-3,765
757
541
-1,246
71.2
221
289
Stock issued
392
364
296
960
0
Cash from financing
396
353
288
1,336
22
-3.88
-1.49
-5
-4.92
-3.27
Exchange rate effect
4.82
-27.8
10.1
-9.97
-70.5
56.8
22.3
-1.52
1.78
-4.46
Net change in cash
628
206
129
Free cash flow
235
-152
-153
3,186
-470
-558
-528
-425
-337
-271
Interest paid
0.05
0.27
1.06
1.16
9.03
12.5
12.5
3.81
0.69
0.46
Income taxes paid
1.76
0.2
0.01
0.06
1.36
0.68
4.43
8.17
-0.41
0.37
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. No valuation: the share price is quoted in a different currency than the statements.
Profitability
Metric
Value
How it is calculated
Gross margin
97.3%
Gross profit / revenue.
Operating margin
26.5%
Operating income / revenue.
Pre-tax margin
27.1%
Pre-tax income / revenue.
Net margin
28.9%
Net income / revenue.
FCF margin
-24.4%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-23.1%
Cash from operations / revenue.
Effective tax rate
-6.2%
Income tax / pre-tax income, when pre-tax income is positive.
Return on assets (ROA)
8.5%
Net income / average total assets.
R&D / revenue
41.3%
Research and development expense / revenue.
Capex / revenue
1.2%
Capital expenditures / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
303.5%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
66.4%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
18.4%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
349.6%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
67.8%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Net income growth, 1y
333.1%
Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y
334.8%
EPS vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-17.6%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-10.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-9.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
20.1x
Current assets / current liabilities.
Quick ratio
19.7x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
19.6x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
5.0%
Total liabilities / total assets.
Working capital
€2.93B
Current assets - current liabilities.
Goodwill and intangibles / assets
0.0%
(Goodwill + intangible assets) / total assets.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.29x
Revenue / average total assets.
Fixed asset turnover
12.5x
Revenue / average property, plant and equipment.
Inventory turnover
0.81x
Cost of revenue / average inventory.
Days inventory
452 days
365 x average inventory / cost of revenue.
Receivables turnover
32.6x
Revenue / average receivables.
Days sales outstanding
11 days
365 x average receivables / revenue.
Days payables
1,249 days
365 x average accounts payable / cost of revenue.
Cash conversion cycle
-786 days
Days inventory + days sales outstanding - days payables.
FCF conversion
-84.5%
Free cash flow / net income, when net income is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
€4.87
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
€4.87
Net income per basic share, as reported (split-adjusted).
What was Lakefront Biotherapeutics NV's revenue in fiscal 2025?
Lakefront Biotherapeutics NV reported revenue of €1.11B for fiscal 2025, 303.5% higher than the year before.
Was Lakefront Biotherapeutics NV profitable in fiscal 2025?
Yes. Net income was €320.9M, a net margin of 28.9%.
How much free cash flow did Lakefront Biotherapeutics NV generate in fiscal 2025?
Cash from operations of €257.5M minus capital expenditures of €13.7M left free cash flow of -€271.2M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.